COMMUNIQUÉS West-GlobeNewswire

Multiple Myeloma Research Foundation® (MMRF) Announces New Data from Flagship Research Initiatives at the 22nd International Myeloma Society Annual Meeting
20/09/2025
MMRF continues to drive the critical global research collaborations that lead to scientific breakthroughs and improved patient outcomes NORWALK, Conn., Sept. 20, 2025 (GLOBE NEWSWIRE) -- Today, the Multiple Myeloma [...]
GENFIT annonce l'arrêt de son programme VS-01 dans l'ACLF – le développement de VS-01 est recentré sur l'UCD
19/09/2025
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 19 septembre 2025 – GENFIT (Nasdaq et Euronext: GNFT) , société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de [...]
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
19/09/2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 19, 2025 - GENFIT (Nasdaq and Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with [...]
PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus
19/09/2025
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22
19/09/2025
CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19/09/2025
NOVATO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare [...]
Algernon Announces Preferred Share Class Approved at Annual and Special Meeting
19/09/2025
VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces the voting [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
19/09/2025
SAN CARLOS, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel [...]
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
19/09/2025
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative [...]
Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) f for Crypto Business Through PIPE Transaction
20/09/2025
LOS ANGELES and CARLSBAD, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or “Company”), a California-based global shared intelligent electric mobility [...]
Kensana Health Lands $120 million from GEM, Fuelling a Global Plant Based Medicine Revolution
19/09/2025
The company expects to list on NASDAQ in Q2 2026 NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Kensana Health Inc. (“Kensana”) today announced it has entered into a share subscription facility of up to $120 million with [...]
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
19/09/2025
WARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today expressed its gratitude to the U.S. Department of Health and Human Services (HHS), Secretary [...]
Hydreight Announces Annual General Meeting Results
19/09/2025
VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS, OTC: HYDTF, FSE: SO6) (“ Hydreight ” or the “ Company ”), is pleased to announce that at the 2025 Annual General [...]
TREMFYA (guselkumab) receives positive CHMP opinion for subcutaneous induction regimen in ulcerative colitis, a first for an IL-23 inhibitor
19/09/2025
Recommendation based on the findings from the Phase 3 ASTRO study in ulcerative colitis. 1 , 2 , 3 Guselkumab has the potential to become the first IL-23 inhibitor to offer both subcutaneous and intravenous induction [...]
Sironax Named to 2025 Endpoints 11 List of the Most Promising Biotech Startups
19/09/2025
WALTHAM, Mass., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology company dedicated to discovering and developing transformative therapies for age-related degenerative diseases, today [...]
Acarpia Farmaceutici et EarlyHealth Group élargissent leur partenariat afin d’améliorer l’accès à CARICOM et au Mexique
19/09/2025
MILAN, 19 sept. 2025 (GLOBE NEWSWIRE) -- Acarpia Farmaceutici S.r.l., un fabricant pharmaceutique italien, et EarlyHealth Group, un prestataire mondial de services pharmaceutiques, ont annoncé l’élargissement de leur [...]
Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants
19/09/2025
REDWOOD CITY, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on development of briquilimab, a novel antibody therapy [...]
Kraig Biocraft Laboratories Expands Spider Silk Manufacturing with Pursuit of Additional Rearing Center
19/09/2025
ANN ARBOR, Mich., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced that it is actively pursuing [...]
SAB BIO Highlights Data in Multiple Presentations at EASD
19/09/2025
-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study- -Data in [...]

Pages